Research use onlyNot for human or veterinary use
Encore Bio Labs CartExplore catalog
ENCORE BIO LABSRESEARCH COLLECTION
IGF1-LR3 — complete Encore Bio Labs reference vialMATERIAL / 10

Reference artwork · Legacy packaging may be shown.
Listed identity and formats take precedence over the image.

Research material

IGF1-LR3

A change in sequence opens a new question about growth-factor signaling. IGF1-LR3 has an extended chain and a specific amino-acid substitution. Research on these analogues explores how molecular design changes interactions with binding proteins, making structure central to its scientific appeal.

CAS
946870-92-4

Formats & reference pricing

USD
Listed formatReference price
1 mg$75 USD

Reference prices describe the listed formats. They do not confirm availability or constitute an offer for sale.

Review product documentation

For laboratory research only. Not for human or veterinary use.

About the reference identity

The name describes two sequence changes

Long R3 IGF-I is named for two modifications to a reference IGF-I sequence. Long describes a 13-amino-acid extension at one end; R3 refers to arginine replacing glutamic acid at position three of the IGF-I portion. These naming details distinguish the analogue from unmodified IGF-I and from other variants.

Long designation
13-amino-acid extension
R3 designation
Arginine at position 3 of the IGF-I portion

Reference identity only; not a test result for current inventory.

01 / Material overview

The specifications.

Catalog identity
IGF1-LR3
CAS
946870-92-4
Listed formats
1 mg
Reference price range
$75 USD
Intended setting
Qualified laboratory or institutional research
Inventory specifications
Independent inventory review pending

02 / Public regulatory context

IGF-1 records and analog boundaries.

An FDA-approved mecasermin product exists, but IGF1-LR3 is a distinct catalog identity and must not be presented as INCRELEX or as an approved IGF-1 drug product.

REGULATORY REFERENCE · STATUS REVIEWED OCT 2026IGF1-LR3

INCRELEX contains mecasermin. IGF1-LR3 is not represented as the same product or molecule.

INCRELEX is an FDA-approved prescription drug product containing mecasermin. This Encore Bio Labs IGF1-LR3 catalog listing is a separate research identity and is not represented as INCRELEX, mecasermin, an FDA-approved drug product, interchangeable, substitutable, or equivalent.

Catalog identity
IGF1-LR3
CAS
946870-92-4
FDA-labeled comparator
INCRELEX · mecasermin
Molecular equivalence
Not represented
Catalog approval status
Not represented as an FDA-approved drug product
FDA enforcement context

IGF1-LR3 is not represented as mecasermin or INCRELEX. In a 2020 compounding warning letter, FDA identified IGF1-LR3 among bulk substances that were not components of FDA-approved human drugs and did not appear on the 503A bulks list in that enforcement context. This page does not present compounding or human-use guidance.

External public records

DailyMed · INCRELEX / mecasermin label FDA · Compounding enforcement record

03 / Supporting records

Documentation.

Read the Encore summary, the scope of related reports and the status of privacy-redacted supplier copies.

No authenticated certificate establishing current-inventory identity or specifications is published for IGF1-LR3 in this catalog.

Encore documentary summary · not a laboratory-issued COA

Report availability
1 related report located
Formats & scope
A source report naming IGF1-LR3 1 mg was located; no privacy-redacted review copy is prepared.
Report authenticity
Laboratory authentication pending
Inventory evidence review
Report-to-inventory correspondence has not been independently established. No purity, quantity or activity result is attributed to current inventory.
Outstanding review
Privacy-safe copy pending: customer-identifying content overlaps analytical material. Obtain an issuer replacement without altering results or the chromatogram.
Product-specific SDS
Not located in the reviewed PDF set; applicability and verification pending.

Document inventory reviewed October 6, 2026. Related reports were commissioned by third parties, not Encore. Original customer details and internal records are not included here.

Privacy-redacted supplier report

Report review pending

Where prepared, these are copies redacted by Encore for privacy, not laboratory-issued public versions or Encore-commissioned tests. Analytical content is not replaced with Encore results.

Copy preparation
0 source files in redacted review copies; 1 source held separately. Duplicate file formats are not additional tests.
Supplier sharing permission
Owner-confirmed for supplied reports; this does not imply a report exists for every product. Report authentication is a separate check.
Privacy review
Release review pending. Retained references and copies elsewhere can still identify the original customer; redaction does not guarantee anonymity.
Downloads
No website copy released. No download is available for this product.
Laboratory-issued public copy
Not available. Encore-prepared redactions are not an issuer reissue.

Obtain a privacy-safe replacement from the issuer. A source is on file; it is not absent.

A public copy does not by itself verify current inventory. No laboratory replacement or delivery date is promised.

Explore summary & report status

04 / A closer look

Common questions.

01Which IGF1-LR3 formats and reference prices are listed?

1 mg: $75 USD. These are catalog quantities and reference prices, not usage instructions, stock confirmation or an offer for sale.

02Where can I find the IGF1-LR3 reports?

Report review pending. The Documentation section on this page lists the reviewed source status and outstanding items for this material. No public PDF is available for this product; an unreleased or missing document is not a certificate of current inventory.

03Is IGF1-LR3 the same as INCRELEX (mecasermin)?

No. INCRELEX is an FDA-approved prescription drug containing mecasermin. IGF1-LR3 is a distinct catalog identity and is not represented as INCRELEX, mecasermin, an approved drug product, or an equivalent substitute.

04Does the INCRELEX label apply to IGF1-LR3?

No. Approved labeling applies to the specific mecasermin product described in that labeling and does not establish the properties or intended use of IGF1-LR3.

05What has FDA said about IGF1-LR3 in compounding enforcement?

FDA has cited IGF1-LR3 in a compounding warning letter as not being a component of an FDA-approved human drug and not appearing on the 503A bulks list at the time of that enforcement action. This catalog does not present compounding, dosing, injection, or human-use instructions.

06Does this page claim anabolic, growth, performance, or body-composition effects?

No. This catalog provides identity, format, regulatory-context, and document-status information only.

Continue the collection

Next in the catalog.

View all materials